| Description | Ianalumab (VAY-736) is a decarboxylated humanized antibody against BAFF-R. Ianalumab can inhibit the interaction between BAFF and BAFF-R and inhibit the protection of apoptosis mediated by BAFF. Ianalumab has antibody dependent cytotoxicity (ADCC) and works by activating effector cells mediated by the immune receptor tyrosine activation motif (ITAM). |
| In vitro | Ianalumab（0.1 μg/mL；72小时）对慢性淋巴细胞白血病（CLL）中的天然杀手细胞显示出强大的抗体依赖性细胞介导的细胞毒性（ADCC），促进细胞因子的产生[1]。 |
| In vivo | Ianalumab (总剂量：100 mg/kg；每周一次；持续2周) 在慢性淋巴细胞性白血病（CLL）的小鼠模型中提高了存活率[1]。当与Ibrutinib联合调节时，Ianalumab (10 mg/kg；每周一次；持续6周) 表现出增强的NK细胞功能[1]。 |
| Synonyms | VAY-736 |
| molecular weight | N/A |
| CAS | 1929549-92-7 |
| Storage | store at low temperature | store at -80°C |
| References | 1. McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019 Feb 12;3(3):447-460. |